StockData
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. (AQST) stock

AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 3/30
$3.70−0.06 (-1.60%)

Close on Nov 17, 2026Market cap $464.39MP/E –Yield –

Aquestive Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Aquestive Therapeutics's price to sales ratio was 8.3× on Nov 11, 2026, against 17.4× a year earlier. Over the last 5 years it ranged from 0.5× to 18.1×, with a median of 4.6×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20268.3×−9.8
2025Dec 31, 202518.1×+12.6
2024Dec 31, 20245.5×+2.7
2023Dec 29, 20232.8×+1.8
2022Dec 30, 20221.0×−2.3
2021Dec 31, 20213.3×+0.1
2020Dec 31, 20203.3×+0.5
2019Dec 31, 20192.7×+0.6
2018Dec 31, 20182.1×–

More Aquestive Therapeutics figures

See a number that looks wrong?